Evidence map›Paper›PMID 18171475›Full record

ArticleBMC infectious diseases2008

Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.

Ahmad R Sedaghat, Robert F Siliciano, Claus O Wilke

Registry-linked trialAbstract read
In one paragraph

Article in BMC infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00908544 (NEW ERA STUDY - HIV and Eradication), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00908544 nacompletednot on this mapstarted 2009, after this paper: background citation

NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0

TypeinterventionalSponsorMUC Research GmbHRan2009 to 2018Enrolled47ConditionsHIV InfectionsArmsPHI-patients, CHI-patients
3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. A novel anti-HIV immunotherapy to cure HIV.AIDS (London, England) · 2017
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Viral latency and potential eradication of HIV-1.Expert review of anti-infective therapy · 2012
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ahmad R SedaghatDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore Maryland 21205, USA. sedaghat@jhmi.edu
Robert F Siliciano
Claus O Wilke

Funding

LATENT VIRAL RESERVOIRS IN HIV1 INFECTIONR01AI043222 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILICIANO, ROBERT F · 1998 to 2013
$3.5M
Significance of Low Level Viremia in Patients on HAARTR37AI051178 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILICIANO, ROBERT F · 2007 to 2016
$2.4M
SIGNIFICANCE OF LOW LEVEL VIREMIA IN PATIENTS ON HAARTR01AI051178 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILICIANO, ROBERT F · 2002 to 2006
$1.8M
Determinants of RNA virus evolutionR01AI065960 · NIAID · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI NOVELLA, ISABEL S · 2005 to 2009
$1.7M
NIAID NIH HHS AI 065960NIAID NIH HHS AI43222NIAID NIH HHS AI51178NIAID NIH HHS R01 AI043222NIAID NIH HHS R01 AI051178NIAID NIH HHS R01 AI065960NIAID NIH HHS R37 AI051178
6 · The paper itself

Abstract

backgroundIn the setting of highly active antiretroviral therapy (HAART), plasma levels of human immunodeficiency type-1 (HIV-1) rapidly decay to below the limit of detection of standard clinical assays. However, reactivation of remaining latently infected memory CD4+ T cells is a source of continued virus production, forcing patients to remain on HAART despite clinically undetectable viral loads. Unfortunately, the latent reservoir decays slowly, with a half-life of up to 44 months, making it the major known obstacle to the eradication of HIV-1 infection. However, the mechanism underlying the long half-life of the latent reservoir is unknown. The most likely potential mechanisms are low-level viral replication and the intrinsic stability of latently infected cells.

methodsHere we use a mathematical model of T cell dynamics in the setting of HIV-1 infection to probe the decay characteristics of the latent reservoir upon initiation of HAART. We compare the behavior of this model to patient derived data in order to gain insight into the role of low-level viral replication in the setting of HAART.

resultsBy comparing the behavior of our model to patient derived data, we find that the viral dynamics observed in patients on HAART could be consistent with low-level viral replication but that this replication would not significantly affect the decay rate of the latent reservoir. Rather than low-level replication, the intrinsic stability of latently infected cells and the rate at which they are reactivated primarily determine the observed reservoir decay rate according to the predictions of our model.

conclusionThe intrinsic stability of the latent reservoir has important implications for efforts to eradicate HIV-1 infection and suggests that intensified HAART would not accelerate the decay of the latent reservoir.

Indexed as

Antiretroviral Therapy, Highly ActiveModels, BiologicalVirus ReplicationCD4-Positive T-LymphocytesHIV-1HIV InfectionsHumansViral LoadVirus Latency

Identifiers

PMID18171475
PMCPMC2254415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.